NASDAQ: BLTE - Belite Bio, Inc

半年間の収益性: +81.24%
セクタ: Healthcare

プロモーションスケジュール Belite Bio, Inc

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.

さらに詳しく
The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Цена ао 67.55
EBITDA -0.0057
Число акций ао 0.02659 млрд
P/BV 14.39
EV/EBITDA -1.08
ISIN US07782B1044
Сайт https://belitebio.com
Валюта usd
IPO date 2022-04-29
Sector Health Care
Industry Biotechnology
Валюта отчета usd
1日あたりの価格変動: +1.41% (66.61)
週ごとの価格変動: +21.06% (55.8)
月ごとの料金変更: +39.13% (48.55)
3ヶ月間の価格変動: +34.83% (50.1)
半年間の価格変動: +81.24% (37.27)
年間の価格変動: +84.66% (36.58)
年初からの価格変動: +76.79% (38.21)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 13.5 1
P/E 0 0
EV/EBITDA -36.24 0
合計: 1.13

効率

名前 意味 学年
ROA, % -33.42 0
ROE, % -34.98 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0283 10
合計: 9

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 448.58 10
収益性 EPS, % 398.1 10
合計: 8
さらに詳しく

機関 音量 共有, %
Armistice Capital, LLC 36000 0.12
Morgan Stanley 22421 0.08
State Street Corporation 17557 0.06
Cubist Systematic Strategies, LLC 16882 0.06
Marshall Wace LLP 16011 0.05
JP Morgan Chase & Company 14267 0.05
Point72 Asset Management, L.P. 7700 0.03
Geode Capital Management, LLC 6700 0.02
Jump Financial, LLC 5200 0.02
Renaissance Technologies, LLC 4900 0.02

ETF 共有, % 年間の利益率, % 配当金, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76712 77.329244365683 0.33
SPDR S&P Emerging Markets Small Cap ETF 0.03878 16.198378276447 3.03583
SPDR S&P China ETF 0.02029 20.508811824901 3.40103
SPDR Portfolio Emerging Markets ETF 0.00475 23.634735899731 3.1879



スーパーバイザー 役職 支払い 生年
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (45 年)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (39 年)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (57 年)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

住所: United States, San Diego. CA, 12750 High Bluff Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://belitebio.com